Boston Scientific (BSX) is under renewed investor scrutiny after a series of voluntary Class II recalls for its CRE and CRE Pro Wireguided gastrointestinal devices, following FDA reports of potential sterile pouch breaches across more than 81,000 units worldwide.
See our latest analysis for Boston Scientific.
Boston Scientific's share price has come under sustained pressure, with the stock down 29.8% on a 90 day share price return and 54.0% on a year to date share price return. The 1 year total shareholder return has declined 59.0%, suggesting recent recall headlines and quality concerns are weighing on sentiment despite ongoing clinical trial milestones such as the FARADIGM study.
If recent volatility around Boston Scientific has you reassessing risk, it can help to broaden your watchlist with other healthcare technology opportunities using our screener for 39 healthcare AI stocks.
Boston Scientific now trades at what looks like a steep discount to both analyst targets and some intrinsic value estimates after the recall driven sell off. Is this caution a warning sign or a mispriced opportunity?
Most Popular Narrative: 55.9% Undervalued
Compared with Boston Scientific's last close at $43.58, the most followed narrative points to a fair value of $98.90, setting up a wide gap in expectations.
The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we''ve seen in the recent price dips.
According to Bill_S, the fair value hinges on how Boston Scientific absorbs near term earnings dilution, leans on higher growth neurovascular exposure, and prices in a richer profit profile over time. The tension between a lower share price and a higher earnings power story sits at the heart of this valuation. If you want to see how revenue mix, margin assumptions, and profit multiples all connect in one coherent roadmap, the full narrative lays those moving parts out in detail.
Result: Fair Value of $98.90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Boston Scientific still faces meaningful risks, including further recall-related headlines or integration setbacks on the Penumbra deal, which could undermine confidence in the valuation case.
Find out about the key risks to this Boston Scientific narrative.
Next Steps
With sentiment around Boston Scientific clearly split between caution and optimism, this is a moment to move quickly and pressure test the numbers yourself, then weigh those findings against the 4 key rewards.
Looking for more investment ideas beyond Boston Scientific?
If the Boston Scientific story has you rethinking your portfolio, this is the moment to widen your search and compare other clear, data driven opportunities side by side.
- Pinpoint reliability first by scanning companies in our 79 resilient stocks with low risk scores that aim to keep volatility in check while still offering room for growth.
- Target value upfront by reviewing businesses in the screener containing 20 high quality undiscovered gems that many investors may be overlooking despite solid fundamentals.
- Strengthen your core holdings by checking stocks in the solid balance sheet and fundamentals stocks screener (48 results) that focus on resilient finances and durable performance potential.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com